All Topics
All Topics
Technology
Technology
AI
AI
Business
Business
Entertainment
Entertainment
News
News
Programming
Programming
Science
Science
Design
Design
Environment
Environment
Finance
Finance
Crypto
Crypto
Politics
Politics
Sports
Sports
Education
Education
Gaming
Gaming
Art
Art
Music
Music
Health
Health
Security
Security
Books
Books
Food
Food
Travel
Travel
Personal
Personal
Bluesky
Twitter
First reported by bsky
Biohacker Bryan Johnson diagnosed with incurable autoimmune disease autoimmune gastritis

Biohacker Bryan Johnson Diagnosed with Incurable Autoimmune Gastritis

By

Faustine Ngila

3h ago· 4 min readenNews

Summary

Bryan Johnson, the tech entrepreneur and longevity advocate known for his extreme $2 million/year health regimen, has been diagnosed with autoimmune gastritis (AIG) — an incurable condition where the immune system attacks the stomach lining. The disease can cause nutritional deficiencies, anemia, and increased stomach cancer risk. Johnson disclosed the May diagnosis in a social media post, highlighting the irony that someone obsessed with biological optimization now faces an incurable autoimmune disease.

Source

bskyBiohacker Bryan Johnson Diagnosed with Incurable Autoimmune Gastritisimpactnews-wire.com

Key quotes

· 3 pulled
He disclosed in a social media post that he was diagnosed in May with autoimmune gastritis (AIG), a condition in which the immune system attacks cells in the stomach lining.
The condition can lead to nutritional deficiencies, anemia and, over time, an increased risk of stomach cancer.
Bryan Johnson, the tech entrepreneur turned longevity advocate who says he spends $2 million a year on his health, now says he has been diagnosed with an incurable autoimmune disease that causes his stomach to attack itself.
Snippet from the RSS feed
Bryan Johnson, the tech entrepreneur turned longevity advocate who says he spends $2 million a year on his health, now says he has been diagnosed with an incurable autoimmune disease that causes hi…

You might also wanna read

Comments

Sign in to join the conversation.

No comments yet. Be the first.